NCT01769677已完成1 期
A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of Two 45-mg and One 90-mg Hydrocodone Bitartrate Extended-Release Tablet
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Maximum observed plasma drug concentration (Cmax)
研究概览
简要总结
The primary objective of this study is to assess the bioequivalence of two 45-mg hydrocodone bitartrate extended-release tablets and one 90-mg hydrocodone bitartrate extended-release tablet.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Written informed consent is obtained.
- •The subject can read, speak, and write in English.
- •The subject is a man or woman 18 through 45 years of age, with a body mass index (BMI) of 20.0 to 30.0 kg/m2, inclusive.
- •The subject is in good health as determined by medical and psychiatric history, physical examination, ECG, serum chemistry, hematology, urinalysis, and serology.
- •Women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing potential, be using an acceptable method of contraception, and agree to continued use of this method for the duration of the study and for 30 days after discontinuation of study drug. Acceptable methods of contraception include abstinence or an intrauterine device (known to have a failure rate of less than 1% per year).
- •The subject has a negative alcohol test and urine drug screen.
- •The subject must be willing and able to comply with study restrictions and to remain at the study center for the required duration of each study drug period during the study.
排除标准
- •The subject has any clinically significant uncontrolled medical conditions (treated or untreated).
- •The subject has a clinically significant deviation from normal in ECG or physical examination findings, as determined by the investigator or the medical monitor.
- •The subject has habitually consumed, within the past 2 years, more than 21 units of alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse as defined by the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition, Text Revision (DSM-IV-TR, American Psychiatric Association 2000). NOTE: A unit of alcohol is equal to 1 ounce of hard liquor, 5 ounces of wine, or 8 ounces of beer.
- •The subject is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
- •The subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including GI surgery; a history of appendectomy is allowed).
- •The subject has received any investigational drug within 30 days or 5 half-lives (whichever is longer) before the 1st dose of study drug, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before the 1st dose of study drug.
- •The subject has a known sensitivity or idiosyncratic reaction to hydrocodone or hydromorphone, their related compounds, or to any metabolites, or naltrexone, or any compound listed as being present in a study formulation.
- •Other exclusion criteria apply.
研究组 & 干预措施
Treatment Group AB
Experimental
Subjects in this group will receive study drug in the following sequence:
- Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference).
- Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test).
干预措施: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B). (Drug)
Treatment Group BA
Experimental
Subjects in this group will receive study drug in the following sequence:
- Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test).
- Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference).
干预措施: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B). (Drug)
结局指标
主要结局
Maximum observed plasma drug concentration (Cmax)
时间窗: Up to 72 hrs after each dose of study drug
To assess the bioequivalence between 45-mg tablets and one 90-mg tablet of the hydrocodone bitartrate extended-release tablet.
Area under the plasma drug concentration by time curve AUC0-∞
时间窗: Up to 72 hrs after each dose of study drug
To assess bioequivalence between two 45-mg tablets and one 90-mg tablet of the hydrocodone bitartrate extended-release tablet.
次要结局
- Time to maximum observed plasma drug concentration (tmax)(Up to 72 hrs after each dose of study drug)
- AUC from time 0 to 72 hours after study drug administration (AUC0-72)(Up to 72 hrs after each dose of study drug)
- AUC from time 0 to the time of the last measurable drug concentration (AUC0-t)(Up to 72 hrs after each dose of study drug)
- Percentage extrapolation, 100x(AUC0-∞-AUC0-t)/AUC0-∞)(Up to 72 hrs after each dose of study drug)
- Apparent plasma terminal elimination rate constant (λz) and associated elimination half life (t½)(Up to 72 hrs after each dose of study drug)
- Recording of Adverse Events(Adverse events will be collected for the duration of the study which is approximately 7 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release TabletPainNCT01758978Teva Branded Pharmaceutical Products R&D, Inc.54
已完成
1 期
A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic ImpairmentHepatic ImpairmentNCT01319279Cephalon16
已完成
不适用
Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy VolunteersPregnancy RelatedNauseaNCT05498233Valenta Pharm JSC28
已完成
1 期
Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL SyrupBronchitisNCT02858193Dompé Farmaceutici S.p.A30
已完成
1 期
Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted ParticipantsHealthyNCT02220218Janssen Research & Development, LLC2